BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8976815)

  • 21. [Amifostine: current and future applications in cytoprotection].
    Lenoble M
    Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
    Peters GJ; van der Vijgh WJ
    Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
    Rohilla S; Dureja H; Chawla V
    Curr Cancer Drug Targets; 2019; 19(10):765-781. PubMed ID: 30914026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future directions in non-small cell lung cancer.
    Schiller JH
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(36 Suppl Fur Die):1-6. PubMed ID: 9417379
    [No Abstract]   [Full Text] [Related]  

  • 29. The current status of toxicity protectants in cancer therapy.
    Schuchter LM; Luginbuhl WE; Meropol NJ
    Semin Oncol; 1992 Dec; 19(6):742-51. PubMed ID: 1334280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amifostine and combined-modality therapeutic approaches.
    Mehta MP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current role of chemotherapy protectors in cancer treatment.
    Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
    Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
    Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
    Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytoprotective effects of amifostine in the treatment of tumors].
    Burkon P; Petýrek P; Spurný V
    Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
    van der Vijgh WJ; Peters GJ
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
    Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
    Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.